Business
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trialExtended cash runway expected to support operations through end of 1Q 2024Presented new data at the Society for Investigational Dermatology 2022 Annual Meeting suggesting ALRN-6924’s potential to protect against chemotherapy-induced alopeciaReported new data from healthy volunteer study demonstrating ALRN-6924-induced cell cycle arrest in hair follicles and suggesting that higher levels of ALRN-6924 may generally prolong cell cycle arrestStrengthened management team with appointment of Susan L. Drexler as interim Chief Financial Officer (CFO) BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the second quarter ended June 30, 2022. “As we announced earlier this month, we are pleased that we have extended our cash runway, which is now expected to fund our operations through the end of 1Q 2024. We expect that our cash resources will support key planned data readouts from our ongoing breast cancer trial, including initial data in 4Q 2022, an interim readout in 2Q 2023, and topline results in 3Q 2023, in addition to pivotal trial readiness activities, subject to the breast cancer trial data and discussions with the FDA,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron. Dr. Aivado continued, “Supportive care continues to be a severely underserved medical need. Available pharmacologic therapies, like G-CSF for severe neutropenia and EPO for anemia, have limited efficacy and are associated with severe toxicities of their own. For several other toxicities, like alopecia, there are no approved pharmacologic therapies. Chemotherapy-induced toxicities frequently can lead to dose reductions and delays, significant adverse impact on quality of life, and premature treatment discontinuations. By delivering a chemoprotective agent that can effectively protect multiple tissue types simultaneously, we have the potential to usher in a new era in supportive care where ‘whole patient care’ becomes the accepted and expected standard....